FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Core Insights - FibroGen, Inc. is rebranding to Kyntra Bio, focusing on oncology and rare disease assets, with trading under the new Nasdaq symbol "KYNB" starting January 8, 2026 [1][6] Company Transformation - 2025 was a pivotal year for the company, marked by the sale of FibroGen China, repayment of a senior secured term loan, and extending its cash runway into 2028 [2] - The rebranding reflects a sharpened focus on mid- and late-stage assets, particularly FG-3246, a CD46 targeting antibody drug conjugate, and FG-3180, a companion PET imaging agent in a Phase 2 trial for prostate cancer [2][4] Product Development and Clinical Trials - Roxadustat, approved in multiple countries for treating anemia in chronic kidney disease, is being evaluated for a Phase 3 trial in the U.S. for lower-risk myelodysplastic syndromes [4] - FG-3246 is in Phase 2 development for metastatic castration-resistant prostate cancer, with interim results from the ongoing monotherapy trial expected in the second half of 2026 [7] - The company has received Orphan Drug Designation from the FDA for myelodysplastic syndromes and submitted a pivotal Phase 3 clinical trial protocol for roxadustat [7] Corporate Strategy - The company is refreshing its corporate website to align with its new strategic direction [3] - Kyntra Bio aims to create a significant impact for patients and shareholders through its focused approach on novel therapies [2][6]